Has the latest bailout resolved the Greek debt crisis, or simply postponed Greece's exit from the euro? And has the crisis revealed deeper problems with the structure of the Eurozone—and a threat to the world financial system? Professor Andrew Metrick, the director of the Yale Program on Financial Stability, talks with scholars and investors.
Andrew MetrickDeputy Dean & Michael H. Jordan Professor of Finance and Management
Andrew Metrick joined the Yale School of Management in 2008 as a professor of finance. He has previously held faculty positions in the finance department at Wharton and the economics department at Harvard. In the 2009-2010 academic year, he was on leave working for the Council of Economic Advisers. He is also a Research Associate at the National Bureau of Economic Research and the Director of the Yale Program on Financial Stability. Professor Metrick’s current research and teaching is focused on financial stability, including the regulation of systemic risk, the activities of complex financial institutions, and the causes and consequences of the financial crisis of 2007-2009. His past work has been in financial intermediation more generally, with a focus on investment management and corporate governance. Metrick has been honored with more than a dozen teaching awards and distinctions, including two years (2003 and 2007) as the highest-rated professor in the Wharton MBA program. In 1998, he received the highest teaching honor at Harvard College, the Joseph R. Levenson Memorial Teaching Award, and in 2005, he received the highest teaching honor at the University of Pennsylvania, the Lindback Award.
Kyriacos Sabatakakis '86 YCManaging Director, South Eastern Europe, Accenture
Dr. Kyriacos Sabatakakis is Managing Director, South Eastern Europe, Accenture. He has worked for Accenture in Switzerland, Greece and the Middle-East and has assisted clients in defining and implementing major change programs through strategy, technology, operations, and digital transformation. He specializes in the Communications, Media and High Tech sectors. He has been in charge of the Greek entity of Accenture since 2003, and despite the economic crisis, has managed to grow the local practice significantly and create a strong talent pool in emerging areas like Analytics to serve Accenture clients globally. Dr. Sabatakakis holds a BSc from Yale University, an MSc from Dartmouth College and a PhD from the National Technical University of Athens. He is fluent in Greek, English, French and German.
Mary TannerSenior Managing Director, EVOLUTION Life Sciences Partners
Mary Tanner is Senior Managing Director of EVOLUTION Life Sciences Partners (ELSP). She is also co-founder and Managing Partner of Life Sciences Partners, LLC, a financial advisory firm. At Life Sciences Partners, Tanner specializes in healthcare investment and strategic advisory work. Before joining ELSP, Mary Tanner was Senior Managing Director of both Burrill & Company and Burrill Securities. She is a former Senior Managing Director at Lehman Brothers, Bear Stearns and Peter. J. Solomon Company. At Lehman Brothers, with Frederick Frank, she headed a global healthcare investment banking franchise for over twenty years. Tanner has devoted more than 25 years to the global healthcare and biotechnology industry. Her expertise includes the ethical pharmaceutical industry, biotechnology, diagnostics, medical devices, healthcare services, cosmetics and consumer medicines, as well as green technologies in chemicals. In addition to her well known work with large companies, she specializes in domestic and cross-border transactions between large and small companies, including corporate partnering and minority investments and cross-border mergers. Tanner has directed over 500 mergers and acquisitions, over 130 initial public offerings and hundreds of financings. Tanner’s clients have included Pfizer in its $60 billion acquisition of Pharmacia, Amgen in its $16 billion acquisition of Immunex, Rhône-Poulenc in its acquisition of Rorer, followed by representing Rhône-Poulenc Rorer in its acquisition of U.K. company Fisons, and BASF/BASF Pharma, in its acquisition of U.K. Boots Pharmaceuticals. Tanner received a B.A. magna cum laude from Harvard University. Ms. Tanner is a member of the Board of Directors of Lineagen, Inc., a molecular diagnostic company, and Genticel , S.A., an immuno oncology company. She serves on the Dean’s Council of the Yale Medical School and the Yale School of Organization and Management Advisory Board. Ms. Tanner has been honored for her contributions to biotechnology with numerous awards, including the highest award of Springboard Enterprises, the Oracle, for professional accomplishment and mentoring of women entrepreneurs.
Stavros Thomadakis '68 YCChairman of the Board, University of Aegean and member of the Hellenic Council for Corporate Governance
Stavros is emeritus professor of financial economics at the University of Athens. Educated at Yale (B.A.) and the Sloan School, M.I.T. (M.Sc., Ph.D.), he has taught at Baruch College and M.I.T. He has authored a number of books and published many scholarly articles. His recent papers deal with the history of the Athens Stock Exchange, market regulation, prolegomena to the Greek crisis, the liquidity shortage in post-bailout Greece. His public service includes chairmanship of the Hellenic Capital Market Commission at foundation (1996-2004); the European Committee of the International Organization of Securities Commissions (2002-2004); the Public Interest Oversight Board (2005-2011) overseeing professional accountants’ global standards. He has been member of the board of the European Investment Bank. Currently he is chairman of the board of the University of the Aegean and member of the Hellenic Council for Corporate Governance. As of January 1, 2015 he is chairman of the International Ethics Standards Board for Accountants (IESBA).